Related Experiment Video
Updated: Jul 25, 2026
12:50
Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
Changes in premorbid brain volume predict Alzheimer's disease pathology
L C Silbert1, J F Quinn, M M Moore
1Aging and Alzheimer's Disease Center, Department of Neurology, Oregon Health and Science University, Portland 97201, USA. silbertl@ohsu.edu
Neurology
|August 27, 2003
Summary
Changes in MRI brain volumes over time predict Alzheimer
Area of Science:
- Neurology
- Neuroimaging
- Pathology
Background:
- Alzheimer disease (AD) is characterized by neurodegeneration.
- Accurate biomarkers are needed to track AD progression.
Purpose of the Study:
- To determine if antemortem MRI brain volume changes predict AD pathology.
- To assess the validity of MRI volumetric measurements as biomarkers for AD progression.
Main Methods:
- Longitudinal MRI volumetric data were collected from 39 subjects followed until death.
- Postmortem brain tissue was analyzed for senile plaque (SP) and neurofibrillary tangle (NFT) severity.
- Relationships between antemortem MRI volumes and postmortem pathology were examined.
Main Results:
- Total brain volume change correlated with cortical NFT accumulation.
- Ventricular cerebrospinal fluid (CSF) volume increase related to both cortical NFT and SP.
- Last hippocampal volume correlated with hippocampal NFT burden.
Conclusions:
- Antemortem MRI volumes are valid biomarkers for AD pathologic progression.
- Ventricular volume enlargement rate can monitor disease progression or treatment response in clinical trials targeting NFT and SP pathology.
More Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...